141.69 0.00 (0.00%)
After hours: 4:32PM EDT
|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||141.17 - 143.77|
|52 Week Range||133.82 - 178.86|
|PE Ratio (TTM)||6.23|
|Earnings Date||May 16, 2018 - May 21, 2018|
|Forward Dividend & Yield||1.36 (0.89%)|
|1y Target Est||182.69|
Depomed (DEPO) has adopted a three-pronged business strategy with three key elements: maintain, build, and grow. Depomed aims to maintain its Nucynta franchise of pain products through the commercialization agreement it entered into with Collegium Pharmaceutical in December 2017. Under this agreement, Depomed granted commercialization rights for the Nucynta franchise of pain products to Collegium Pharmaceutical in the US.
After months of inaction by the federal government on the crisis regarding opioid abuse, Attorney General Jeff Sessions announced the creation of a task force charged with looking at how drug makers and ...
WASHINGTON (AP) — The Justice Department said Tuesday it will support local officials in hundreds of lawsuits against manufacturers and distributors of powerful opioid painkillers that are fueling the nation's drug abuse crisis.
AmerisourceBergen must enact sweeping reforms that address its role in the opioid crisis, says Teamsters' Treasurer Ken Hall.
Ohio on Monday accused four major pharmaceutical distributors of ignoring their responsibilities to ensure that opioids were not being diverted for improper uses, contributing to a drug abuse epidemic ...
McKesson Corporation today announced the determination of the Full Tender Offer Consideration, as shown in the table below, for its previously announced cash tender offer to purchase up to $1,100,000,000 combined aggregate purchase price of its outstanding 6.000% Notes due 2041 , 7.650% Debentures due 2027 , 4.883% Notes due 2044 , 4.750% Notes due 2021 and 7.500% Notes due 2019 .
McKesson Corporation today announced the early tender results as of the Early Tender Time in connection with its previously announced cash tender offer to purchase up to $1,100,000,000 combined aggregate purchase price of its outstanding 6.000% Notes due 2041 , 7.650% Debentures due 2027 , 4.883% Notes due 2044 , 4.750% Notes due 2021 and 7.500% Notes due 2019 .
LONDON, UK / ACCESSWIRE / February 21, 2018 / Active-Investors.com has just released a free earnings report on McKesson Corp. (NYSE: MCK ). If you want access to this report all you need to do is sign ...
Pharmaceutical distributors enjoy a competitive advantage that’s tough to crack, writes Vitaliy Katsenelson.
McKesson and Cardinal Health are alleged to have sent more than 12 million opioid doses to a single pharmacy in West Virginia over an eight-year period, according to a House committee probe.
A possible Walgreens buy of AmerisourceBergen as well as the latest Amazon rumor threaten to upend drug and medical supplies distribution.
Shares of health-care distributors fell Tuesday on news the sector could experience more consolidation and heightened competition from retail giant Amazon.com Inc.
Moody's Investors Service ("Moody's") assigned a Baa2 rating to McKesson Corporation's (McKesson) new Euro and US note offerings. All of McKesson's existing note and short term ratings remain ...
In front of financiers and other potential investors at last month's J.P. Morgan Healthcare Conference, McKesson Corp. CEO John Hammergren highlighted the company's distribution of so-called "destruction pouches" as a way of taking unused opioid painkillers out of circulation. Along with a national, real-time network identifying potential misused prescriptions, the drug deactivation pouches are one of the ways that San Francisco-based McKesson (MCK) — one of the big three medical distributors nationally — says it is fighting an opioid crisis that has pulled the company into 192 legal complaints and killed tens of thousands of people. "We're exploring those (pouches) in different markets," Hammergren said.
NEW YORK, Feb. 07, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Zions ...
The Offer will expire at 11:59 p.m., New York City time, on March 7, 2018, unless extended or earlier terminated by the Company, with respect to any or all series of Notes (such date and time, as the same may be extended or earlier terminated, with respect to any or all series, the "Expiration Time"). Holders must validly tender and not properly withdraw their Notes at or prior to 5:00 p.m., New York City time, on February 21, 2018, unless extended by the Company, with respect to any or all series of Notes (such date and time, the "Early Tender Time") in order to be eligible to receive the Full Tender Offer Consideration (defined below), which includes an early tender payment of $50 per $1,000 principal amount of Notes (the "Early Tender Payment"). Holders that validly tender their Notes after the Early Tender Time and at or prior to the Expiration Time will not be eligible to receive the Early Tender Payment and will only be eligible to receive the Full Tender Offer Consideration minus the Early Tender Payment (the "Late Tender Offer Consideration").